With the help of TBWA\Chiat\Day New York, pharma giant Moderna is demystifying mRNA science for the average consumer. This ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Vaccine stocks have struggled since RFK Jr.'s appointment to health secretary, with Moderna and Pfizer seeing the deepest ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

RFK Jr. has developed a reputation as a vaccine skeptic and pushed conspiracy theories including one linking vaccines to ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Next-generation COVID-19 vaccine: Moderna shared positive Phase 3 vaccine efficacy and immunogenicity data for its next-generation COVID-19 vaccine (mRNA-1283) at its R&D Day event in September 2024.